This week in drug discovery (9-13 December)
News round-up for 9-13 December by DDW Senior Digital Content Editor Diana Spencer.
It’s been a big week for cell and gene therapies (CGTs) as the first in vivo BCMA CAR-T candidate reaches the clinic and a new discovery could lead to a gene therapy that reverses a significant cause of stillbirth and premature delivery.
The top stories:
Scientists discover dangerous side-effect of CRISPR technique
Researchers have uncovered that a molecule used to increase the efficiency of CRISPR-Cas9 gene editing destroys parts of the genome.
Gene therapy could prevent stillbirth and premature delivery
The first gene therapy to potentially reverse a significant cause of stillbirth and premature delivery is being developed by a team at University of Florida (UF) Health.
First in vivo BCMA CAR-T candidate reaches the clinic
A clinical trial has launched in China of ESO-T01, an immune shielded lentiviral vector that reprograms T lymphocytes in vivo into BCMA CAR-T cells, for the treatment of multiple myeloma.
Positive initial results from trial of CD19 CAR-T in blood cancers
Synthekine has announced positive initial results from a Phase I study of SYNCAR-001 + STK-009 for the treatment of relapsed or refractory CD19+ haematologic malignancies.
MRC launches new £50m UK centres to develop gene therapies
The Medical Research Council (MRC), part of UKRI, is launching its first two Centres of Research Excellence (CoRE), which will develop transformative new advanced therapeutics for currently untreatable diseases.
